You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
In cardiac cells, phospholamban is a potent inhibitor of sarcoplasmic reticulum calcium (Ca2+) transport. Overexpression of mutant forms of phospholamban may result in beneficial or detrimental effects on intracellular Ca2+ handling and cardiac systolic and diastolic function. Mutations in phospholamban have also been linked to human cardiomyopathies, providing important insights into the underlying disease mechanisms and the key role of phospholamban in myocardial excitation-contraction coupling. This Perspective discusses new advances in our understanding of the role of phospholamban in intracellular Ca2+ handling and the development of human and murine cardiomyopathies.
